Literature DB >> 3161932

3H-cyproterone acetate: binding characteristics to human uterine progestagen receptors.

H J Grill, B Manz, W Elger, K Pollow.   

Abstract

The availability of tritium labeled cyproterone acetate (CPA) facilitated the systematic investigation of the binding characteristics of this compound for human uterine progesterone receptors (PgR). The binding parameters of 3H-CPA are compared to those of 3H-R5020 and 3H-progesterone. The rate constants of association (k1M-1sec-1) to PgR were 7.8 X 10(3) for 3H-R5020, 4.5 X 10(4) for 3H-progesterone and 4.0 X 10(4) for 3H-CPA. The rate constants of dissociation (k-1, sec-1) were 3.6 X 10(-5) for 3H-R5020, 21.3 X 10(-5) for 3H-progesterone and 17.8 X 10(-5) for 3H-CPA. The Kd-values (M), as obtained by titration analysis and subsequent Scatchard plot analysis were 1.2 X 10(-9) for 3H-R5020, 6.0 X 10(-9) for 3H-progesterone and 5.2 X 10(-9) for 3H-CPA. On sucrose density gradient analysis binding in the 3.5, 5 and 8 S area could be observed using 3H-R5020. For 3H-progesterone and 3H-CPA binding was exclusively found in the 5 S area. The specificity of the steroid binding site of PgR is identical for 3H-R5020 and 3H-CPA. The order of potency of binding for various competitors decreases identically for both radioactive ligands: R5020 less than progesterone less than R1881 less than CPA less than dihydrotestosterone less than dexamethasone less than cyproterone less than 15 beta-OH-cyproterone. CPA resembles progesterone very closely in its binding characteristics to human uterine PgR.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3161932     DOI: 10.1007/bf03350668

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  16 in total

1.  A simple ultraviolet spectrophotometric method for the determination of protein.

Authors:  W J WADDELL
Journal:  J Lab Clin Med       Date:  1956-08

2.  New antiandrogens and their mode of action.

Authors:  F Neumann; B Schenck
Journal:  J Reprod Fertil Suppl       Date:  1976-09

3.  The progestational activity of different gestagens used for human contraception in the beagle bitch.

Authors:  S Beier; F Haase; B Kosub; B Düsterberg; W Elger
Journal:  Contraception       Date:  1979-12       Impact factor: 3.375

4.  Cyproterone acetate in the treatment of infantile adrenogenital syndrome with precocious puberty.

Authors:  J Beyer; K Demisch; W Wiegelmann; J Happ; F Kollmann; K Schöffling
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1973

5.  Isolation and identification of 15-beta-hydroxy cyproterone acetate as a new metabolite of cyproterone acetate in dog, monkey and man.

Authors:  A S Bhargava; A Seeger; P Günzel
Journal:  Steroids       Date:  1977-09       Impact factor: 2.668

6.  The treatment of precocious puberty with cyproterone acetate.

Authors:  K Rager; R Huenges; D Gupta; J R Bierich
Journal:  Acta Endocrinol (Copenh)       Date:  1973-10

7.  Cyproterone acetate in the treatment of advanced carcinoma of the prostate.

Authors:  R B Smith; P C Walsh; W E Goodwin
Journal:  J Urol       Date:  1973-07       Impact factor: 7.450

8.  [Effects and structure of new antiandrogenic steroids].

Authors:  R Wiechert; H Steinbeck; W Elger; F Neumann
Journal:  Arzneimittelforschung       Date:  1967-09

9.  Receptor binding and biological activity of steroidal and nonsteroidal antiandrogens.

Authors:  A E Wakeling; B J Furr; A T Glen; L R Hughes
Journal:  J Steroid Biochem       Date:  1981-12       Impact factor: 4.292

10.  [Problems of dose finding: sexual hormones (author's transl)].

Authors:  F Neumann; W Elger; Y Nishino; H Steinbeck
Journal:  Arzneimittelforschung       Date:  1977-02
View more
  1 in total

1.  Ab initio fragment molecular orbital study of ligand binding to human progesterone receptor ligand-binding domain.

Authors:  Takanori Harada; Kenji Yamagishi; Tatsuya Nakano; Kazuo Kitaura; Hiroaki Tokiwa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-03-11       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.